BEIGF:OTCMKTS
BeOne Medicines
21,95 $
0,00%
(0,00) 1D
9. jun., 12:49:46 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za BEIGF …
Tržna kapitalizacija
44,66 mrd.
Povprečni promet
0,00
Promet
0,00
52-tedenski najvišji tečaj
24,92 $
52-tedenski najnižji tečaj
21,95 $
Beta
0,84
Št. izdanih delnic
1,43 mrd.
Št. zaposlenih
12 tis.
Tržna kapitalizacija
44,66 mrd.
Povprečni promet
0,00
Promet
0,00
52-tedenski najvišji tečaj
24,92 $
52-tedenski najnižji tečaj
21,95 $
Beta
0,84
Št. izdanih delnic
1,43 mrd.
Št. zaposlenih
12 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
MarketBeat
·
pred 11 urami
BeOne Medicines (NASDAQ:ONC) Stock Rating Cut to Hold at Zacks Research
AD HOC NEWS
·
pred 21 urami
BeOne Medicines stock gained 1.00 percent on October 5 as targets rose
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Vizitka: BeOne Medicines
Generalni direktorJohn Vincent Oyler | John Vincent Oyler
Št. zaposlenih12 tis.
Ustanovljeno28. okt. 2010
Sedež-
Sektor-
Spletno mestobeonemedicines.com